Novartis Ag

Novartis Pharma Gmbh

Naoki Teno

Claudia Betschart

Genji Iwasaki

Junichi Sakaki

Osamu Irie

Rene Lattmann

Martin Missbach

Eva Altmann

Kenji Hayakawa

John Henry Van Duzer

Keiichi Masuya

Ruben Alberto Tommasi

Leslie Wighton McQuire

Takahiro Miyake

Paul David Greenspan

Scott Douglas Cowen

Michihiro Takai

Miyuki Horiuchi

Keigo Gohda

The invention provides compounds of formula I or a pharmaceutically acceptable salt or ester thereof wherein the symbols have meaning as defined, which are inhibitors of cathepsin K and find use pharmaceutically for treatment of diseases and medical conditions in which cathepsin K is implicated, e.g. various disorders including inflammation, rheumatoid arthritis, osteoarthritis, osteoporosis and tumors.

Heteroaryl nitrile derivatives

The invention provides compounds of Formula (I) or a pharmaceutically acceptable salt or ester thereof wherein the symbols have meaning as defined, which are inhibitors of cathepsin K and find use pharmaceutically for treatment of diseases and medical conditions in which cathepsin K is implicated, e.g. various disorders including inflammation, rheumatoid arthritis, osteoarthritis, osteoporosis and tumors. 

Hetereoaryl nitrile derivatives

The invention provides compounds of formula (I) or a pharmaceutically acceptable salt or ester thereof formula (I) wherein the symbols have the meaning as defined in the description. Said compounds are inhibitors of cathepsin K and/or cathepsin S and are useful for the treatment of diseases and medical conditions in which cathepsin K and/or cathepsin S is implicated, e.g. various disorders including neuropathic pain, inflammation, rheumatoid arthritis, osteoarthritis, osteoporosis, multiple sclerosis and tumors. 

Spiro-substituted pyrrolo[2,3-D]pyrimidines as cathepsin inhibitors

The invention provides compounds of Formula I or a pharmaceutically acceptable salt or ester thereof wherein the symbols have meaning as defined, which are inhibitors of cathepsin K and find use pharmaceutically for treatment of diseases and medical conditions in which cathepsin K is implicated, e.g. various disorders including inflammation, rheumatoid arthritis, osteoarthritis, osteoporosis and tumors. 

Pyrrolo pyrimidines as agents for the inhibition of cystein proteases

Dipeptide nitriles

Growing community of inventors

Ibaraki Pref., Japan

Naoki Teno